Human Microbiome Market by Product (Prebiotics, Probiotics, Food, Diagnostic Tests, Drugs), Application (Therapeutic, Diagnostic), Disease (Infectious, Metabolic/Endocrine), Research Technology (Genomics, Proteomics, Metabolomics), and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).
The global Human Microbiome Market size is projected to reach a CAGR of 31.07% from 2023-2030.
The human microbiota consists of the trillions of symbiotic microbial cells harbored by each person mainly bacteria in the gut. Microbes, including bacteria, fungi, and viruses, are disease-causing agent that accumulates over time, and the habitat in the gut transforms their genetic activities and metabolic processes, resulting in an abnormal immune response against the substances and tissues that are normally present in the human body. Several microbiome projects have been launched worldwide with the aim to understand the roles played by these symbionts and their impact on the health of human hosts.
Human gut microbiomes play a major role in improving the efficacy of therapeutic compounds. Over the years, studies have shown that the right combination of microbes in the human body is beneficial for treating different conditions. This association between microbes and specific disease states could generate new opportunities for drug developers (or vaccine manufacturers). With several small innovative players operating in the market, there are various high-growth opportunities for key stakeholders to buy out companies so as to study microbiomes in the hope of identifying new drugs and drug targets for various indications, such as obesity, liver disorders, diabetes, and metabolic disorders. The surging prevalence of respiratory diseases all around the globe is one of the major factors responsible for fostering growth in the market value. Also, increasing focus on immunity development is responsible for boosting the market growth rate. Additionally, the surge in investment in biotechnology and biopharmaceutical industries, the surge in the personal disposable income level, an introduction of technologically driven products in hospitals, increasing investment in the development of advanced medical products and devices, and a rise in the popularity of minimally invasive surgeries, positive affect the market growth rate.
On the other hand, the high initial cost associated with the product is still persistent for many organizations, these arise due to numerous aspects including lack of funds, less floor space, reliability, and infrastructure built, for manual processes. Furthermore, these trucks are operated in systematic spaces using the predefined route and movement of products. This results in lesser flexibility for industries that require forklift trucks for multiple purposes.
The COVID-19 pandemic has created massive disruptions to clinical trial research across the world. As in other aspects of life, the virus has severely affected the ability to conduct trials in safe and effective ways. This is especially true when considering that trials often deal with vulnerable populations who are most at risk from exposure to COVID-19. COVID-19 has adversely impacted and could continue to adversely impact the businesses of other companies, including their preclinical studies and clinical trials of microbiome-based therapeutics and diagnostic products. However, with the relaxation of government restrictions related to the pandemic and the emergence of virtual clinical trials, R&D activities started their recovery from 2021 onward.
The market for human microbiomes is expanding quickly as a result of the increased study of the microbiome and its impact on human health as well as raising public awareness of the possibilities of microbiome-based goods and cures. In order to enhance human health outcomes, there is an urgent need for novel treatment alternatives that can target the microbiome. Chronic disorders including obesity, diabetes, and inflammatory bowel disease are on the rise. In the upcoming years, it is anticipated that the market for probiotics, prebiotics, microbiome sequencing, analysis services, and therapies based on the microbiome will all expand. Pharmaceutical firms, biotechnology firms, and diagnostic firms are some of the major market participants. However, the market for human microbiome-based goods and therapies has enormous potential for innovation and expansion, but it also necessitates ongoing investment in regulatory monitoring, research, development, and manufacturing.
Asia Pacific to Dominate the Market